Oncology Medical News

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. Recommendations on the use of 18F-FDG PET in oncology

3. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials

4. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer

5. Sentinel node biopsy is important in mastectomy for ductal carcinoma in situ

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Elevated expression of microRNAs 155, 203, 210 and 222 in pancreatic tumors is associated with poorer survival
International Journal of Cancer, 09/21/09

Greither T et al. – This study provides the first evidence for an oncogenic activity of miR-155, miR-203, miR-210 and miR-222 in the development of pancreatic cancer as has been reported for other tumor types. Furthermore, the putative target genes for these microRNAs suggest a complex signaling network that can affect PDAC tumorigenesis and tumor progression.

Methods

The levels of miR-155, miR-203, miR-210, miR-216, miR-217 and miR-222 were measured by quantitative RT-PCR in a cohort of 56 microdissected pancreatic ductal adenocarcinomas (PDAC)

Results

Significant correlations between elevated microRNA expression and overall survival were observed for miR-155 (RR = 2.50), miR-203 (RR = 2.21), miR-210 (RR = 2.48), and miR-222 (RR = 2.05)
Tumors from patients demonstrating elevated expression levels of all 4 microRNAs possessed a 6.2-fold increased risk of tumor-related death compared to patients whose tumors showed a lower expression of these microRNAs

<< Previous
Is expression or activation of SRC kinase associated with...

Next >>
Biological indicators of prognosis in Ewings sarcoma: An emerging...